CN112538539A - Kit and system for detecting mycobacterium avium - Google Patents

Kit and system for detecting mycobacterium avium Download PDF

Info

Publication number
CN112538539A
CN112538539A CN202011349925.9A CN202011349925A CN112538539A CN 112538539 A CN112538539 A CN 112538539A CN 202011349925 A CN202011349925 A CN 202011349925A CN 112538539 A CN112538539 A CN 112538539A
Authority
CN
China
Prior art keywords
seq
site
gene
nucleic acid
rrl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011349925.9A
Other languages
Chinese (zh)
Other versions
CN112538539B (en
Inventor
贾鑫淼
杨启文
陈非
李翠丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peking Union Medical College Hospital Chinese Academy of Medical Sciences
Original Assignee
Peking Union Medical College Hospital Chinese Academy of Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peking Union Medical College Hospital Chinese Academy of Medical Sciences filed Critical Peking Union Medical College Hospital Chinese Academy of Medical Sciences
Priority to CN202011349925.9A priority Critical patent/CN112538539B/en
Publication of CN112538539A publication Critical patent/CN112538539A/en
Application granted granted Critical
Publication of CN112538539B publication Critical patent/CN112538539B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Abstract

The present disclosure relates to a kit and a system for detecting mycobacterium avium, the kit comprising a reagent for detecting a molecular marker, wherein the molecular marker comprises at least one of nikA gene, ddpC gene, yejF gene, rrl G2368T locus, rrl T3066A locus, and acpM C177T locus. By identifying the above molecular markers, the present disclosure enables accurate detection of mycobacterium avium.

Description

Kit and system for detecting mycobacterium avium
Technical Field
The present disclosure relates to the field of biotechnology, in particular to a kit for mycobacterium avium detection, use of a reagent for detecting a molecular marker in the preparation of a kit for mycobacterium avium detection, and a system for mycobacterium avium detection.
Background
Nontuberculous mycobacteria (NTM) refer to mycobacteria other than Mycobacterium tuberculosis complex (Mtb) and Mycobacterium leprae, and are widely present in natural environments. About one third of the NTM can cause infection in animals or humans, for example, mycobacterium kansasii, mycobacterium avium, mycobacterium intracellulare, mycobacterium abscessus, mycobacterium cheloniae, and the like.
NTM infection is common in patients with structural lung diseases, and after the infection of human bodies, NTM often invades lung tissues of the patients, so that bronchial tissues and alveolar tissues of the patients are progressively damaged, symptoms similar to pulmonary tuberculosis are caused, the respiratory function of the patients is influenced, and the death of the hosts can be caused in severe cases. In recent years, the infection rate of NTM is rising year by year, and a plurality of researches show that NTM can be infected from person to person, so that NTM detection is carried out timely and accurately, and the method has important social and clinical values.
In the related art, NTM detection mostly relies on target gene sequencing and mass spectrometry detection, wherein common target genes include genes encoding 16S rRNA, 16S-23S rRNA intergenic region (ITS), RNA polymerase β subunit (rpoB), heat shock protein 65(hsp65), and DNA helicase (gyrA/gyrB), sodA gene, recA gene, and the like.
However, in the process of implementing the present disclosure, the inventors found that the resolution of the existing NTM detection technology is low, and NTM species with close relativity cannot be accurately resolved.
Disclosure of Invention
The purpose of the present disclosure is to solve the problem of low resolution in the existing NTM detection technology, and provide a kit and a system capable of accurately detecting mycobacterium avium.
In order to accomplish the above objects, the present disclosure provides, in a first aspect, a kit for detection of mycobacterium avium, the kit comprising a reagent for detecting a molecular marker, wherein the molecular marker comprises at least one of nikA gene, ddpC gene, yejF gene, rrl G2368T site, rrl T306 3066A site, and acpM C177T site.
Optionally, the reagent for detecting a molecular marker comprises a primer pair capable of specifically amplifying the molecular marker, and/or a probe capable of specifically hybridizing to the molecular marker.
Optionally, the primer pair comprises at least one pair of primers shown by SEQ ID NO 1-2, SEQ ID NO 3-4, SEQ ID NO 5-6, SEQ ID NO 7-8, SEQ ID NO 9-10 and SEQ ID NO 11-12.
In a second aspect, the present disclosure provides use of a reagent for detecting a molecular marker including at least one of nikA gene, ddpC gene, yejF gene, rrl G2368T site, rrl T306 3066A site, and acpM C177T site in the preparation of a kit for detection of mycobacterium avium.
Optionally, the reagent for detecting a molecular marker comprises a primer pair capable of specifically amplifying the molecular marker, and/or a probe capable of specifically hybridizing to the molecular marker.
Optionally, the primer pair comprises at least one pair of primers shown by SEQ ID NO 1-2, SEQ ID NO 3-4, SEQ ID NO 5-6, SEQ ID NO 7-8, SEQ ID NO 9-10 and SEQ ID NO 11-12.
In a third aspect, the present disclosure provides a system for mycobacterium avium detection, the system comprising a sequencing device, a computing device, and an output device;
the sequencing device is used for carrying out nucleic acid sequence sequencing on the total nucleic acid of the sample to be tested to obtain a total nucleic acid sequence;
the computing device includes a memory having a computer program stored therein and a processor configured to execute the computer program stored in the memory to effect the determination of:
if the total nucleic acid sequence contains at least one of nikA gene sequence, ddpC gene sequence, yejF gene sequence, rrl G2368T site sequence, rrl T3066A site sequence and acpM C177T site sequence, judging that the mycobacterium avium exists in the sample to be detected;
the output device is used for outputting the judgment result of the computing device.
Optionally, the system further includes a nucleic acid extraction device, where the nucleic acid extraction device is configured to extract nucleic acid from the sample to be detected, so as to obtain total nucleic acid of the sample to be detected.
Optionally, the nucleic acid extraction device comprises a nucleic acid extractor and/or a nucleic acid extraction kit.
Optionally, the sequencing device comprises at least one of a Sanger sequencing platform, Illumina Novaseq, HiSeq Xten, HiSeq2500/2000/4000 sequencing platform.
Through the technical scheme, the accurate detection of the mycobacterium avium can be at least partially realized by identifying molecular markers such as nikA gene, ddpC gene, yejF gene, rrl G2368T site, rrl T3066A site, acpM C177T site and the like.
Additional features and advantages of the disclosure will be set forth in the detailed description which follows.
Detailed Description
The following describes in detail specific embodiments of the present disclosure. It should be understood that the detailed description and specific examples, while indicating the present disclosure, are given by way of illustration and explanation only, not limitation.
A first aspect of the present disclosure provides a kit for mycobacterium avium detection, the kit comprising a reagent for detecting a molecular marker, wherein the molecular marker comprises at least one of nikA gene, ddpC gene, yejF gene, rrl G2368T site, rrl T3066A site, and acpM C177T site.
The inventor of the present disclosure finds that specific molecular markers which are different from other non-tuberculous mycobacteria or tuberculous mycobacteria exist in the mycobacterium avium, namely nikA gene, ddpC gene, yejF gene, rrl G2368T site, rrl T3066A site and acpM C177T site, and by detecting the molecular markers, the mycobacterium avium can be accurately distinguished from other non-tuberculous mycobacteria or tuberculous mycobacteria, so that accurate detection of the mycobacterium avium is at least partially realized.
Specifically, the gene numbers of the above-mentioned molecular markers are shown in Table 1.
TABLE 1
Molecular marker Gene numbering
nikA gene 2718029
ddpC gene 2720266
yejF gene 2720026
rrl G2368T site 2700466
rrl T3066A site 2700466
acpM C177T site 15609381
According to the present disclosure, the reagent for detecting a molecular marker may be selected within a certain range, for example, the reagent for detecting a molecular marker may include a primer pair capable of specifically amplifying the molecular marker, and/or a probe capable of specifically hybridizing to the molecular marker.
According to the present disclosure, the primer pair and the probe may be selected within a certain range, and both the primer pair and the probe satisfying the above requirements may be used in the present disclosure. As a preferred embodiment of the present disclosure, the primer pair may include at least one pair of primers shown by SEQ ID NO. 1-2, SEQ ID NO. 3-4, SEQ ID NO. 5-6, SEQ ID NO. 7-8, SEQ ID NO. 9-10, and SEQ ID NO. 11-12.
Wherein the target molecule markers and nucleotide sequences of the primer pairs are shown in Table 2.
TABLE 2
Figure BDA0002800945270000041
Figure BDA0002800945270000051
A second aspect of the present disclosure provides use of a reagent for detecting a molecular marker including at least one of nikA gene, ddpC gene, yejF gene, rrl G2368T site, rrl T3066A site, and acpM C177T site in preparing a kit for detection of mycobacterium avium.
Alternatively, the reagent for detecting a molecular marker may include a primer pair capable of specifically amplifying the molecular marker, and/or a probe capable of specifically hybridizing to the molecular marker.
Optionally, the primer pair can comprise at least one pair of primers shown in SEQ ID NO 1-2, SEQ ID NO 3-4, SEQ ID NO 5-6, SEQ ID NO 7-8, SEQ ID NO 9-10 and SEQ ID NO 11-12.
A third aspect of the present disclosure provides a system for mycobacterium avium detection, the system comprising a sequencing device, a computing device, and an output device; the sequencing device is used for carrying out nucleic acid sequence sequencing on the total nucleic acid of the sample to be tested to obtain a total nucleic acid sequence; the computing device includes a memory having a computer program stored therein and a processor configured to execute the computer program stored in the memory to effect the determination of: if the total nucleic acid sequence contains at least one of nikA gene sequence, ddpC gene sequence, yejF gene sequence, rrl G2368T site sequence, rrl T3066A site sequence and acpM C177T site sequence, judging that the mycobacterium avium exists in the sample to be detected; the output device is used for outputting the judgment result of the computing device.
Optionally, the system may further include a nucleic acid extraction device, where the nucleic acid extraction device is configured to extract nucleic acid from the sample to be tested, so as to obtain total nucleic acid of the sample to be tested.
Optionally, the nucleic acid extraction device may comprise a nucleic acid extractor and/or a nucleic acid extraction kit.
Alternatively, the sequencing device may be, for example, a second generation sequencing device, for example, the sequencing device may comprise at least one of the Sanger sequencing platform, Illumina Novaseq, HiSeq Xten, HiSeq2500/2000/4000 sequencing platform.
The present disclosure is further illustrated by the following examples, but is not to be construed as being limited thereby.
The starting materials, reagents, instruments and equipment referred to in the examples of the present disclosure may be obtained by purchase, unless otherwise specified.
Example 1
This example serves to illustrate the determination of biomarkers provided by the present disclosure for detection of mycobacterium avium.
81 NTM strains having a complete genome were collected as discovery groups including 7 M.kansasii, 27 M.avium, 6 M.intracellulare, 5 M.tortoise and 36 M.abscessus.
In addition, 384 NTM strains with the original sequencing reads were collected as the first validation set, which included 14 mycobacterium kansasii, 111 mycobacterium avium, 26 mycobacterium intracellulare, 33 mycobacterium cheloni, and 200 mycobacterium abscessus.
And performing comparative genomics analysis on the genome data of the discovery group, and determining the distinguishing genes and the distinguishing SNPs sites in the genome of the 27 strains of mycobacterium avium, which are distinguished from the genomes of other NTM strains, namely nikA gene, ddpC gene, yejF gene, moxC gene, hldE gene, ino 1G 832A site, clpB G2124C site, rrl G447A site, rrl T455A site, rrl G2368T site, rrl T3066A site, Rv 1461G 2133A site, acpM C177T site, Rv 2402G 570C site, rpsK C90G site and pks 13G 672C site.
Aiming at the distinguishing genes and the distinguishing SNPs sites, X2 test and random forest prediction model analysis are carried out in a first verification group, specific genes and specific SNPs sites which are different from the genomes of other NTM strains in the genomes of the mycobacterium avium are screened out from the distinguishing genes and the distinguishing SNPs sites, namely nikA genes, ddpC genes, yejF genes, rrl G2368T sites, rrl T3066A sites and acpM C177T sites, and the specific genes and the specific SNPs sites are used as biomarkers for detecting the mycobacterium avium.
Example 2
This example is used to verify the effect of the biomarkers provided by the present disclosure on the detection of mycobacterium avium.
164 NTM strains with original sequencing reads were collected as a second validation set, including 6 M.kansasii, 48 M.avium, 11 M.intracellulare, 14 M.tortoise and 85 M.abscessus.
And (3) respectively carrying out total nucleic acid extraction on the five mycobacteria by using a nucleic acid extraction kit to obtain the total nucleic acid of each mycobacterium. Then, the total nucleic acid of each mycobacterium obtained above is subjected to second-generation sequencing to obtain the total nucleic acid sequence of each mycobacterium.
Based on at least a part of the molecular markers determined in example 1, the presence or absence of the corresponding molecular marker sequence in the total nucleic acid sequence of each of the above-mentioned mycobacteria is determined, and the mycobacteria containing the corresponding molecular marker sequence is determined to be mycobacterium avium, and the detection result is obtained. The molecular markers targeted for each detection are shown in table 3.
TABLE 3
Figure BDA0002800945270000071
And (3) respectively carrying out ROC analysis on the detection results of the detections 1-9, and determining the specificity, sensitivity and AUC value of each detection, wherein the results are shown in Table 4.
TABLE 4
Detection of Sensitivity of the probe Specificity of AUC
Detection 1 0.987 0.997 0.992
Detection 2 0.987 0.995 0.991
Detection 3 0.887 0.992 0.942
Detection 4 0.987 0.995 0.991
Detection 5 0.987 0.995 0.991
Detection 6 0.987 0.995 0.991
Detection 7 0.717 0.995 0.856
Detection 8 0.635 0.997 0.816
Detection 9 0.692 0.995 0.843
As can be seen from table 4, based on the biomarkers provided by the present disclosure, accurate detection of mycobacterium avium can be achieved.
Comparative example 1
The moxC gene, the hldE gene, the ino 1G 832A site, the clpB G2124C site, the rrl G447A site, the rrl T455A site, the Rv 1461G 2133A site, the Rv 2402G 570C site, the rpsK C90G site and the pks 13G 672C site are respectively used as molecular markers, whether the sequences of the molecular markers exist in the total nucleic acid sequence of the mycobacteria obtained in the example 2 is judged, and the mycobacteria containing the sequences of the molecular markers are judged to be the mycobacterium avium, so that the detection result is obtained.
For each detection result, ROC analysis was performed to determine the specificity, sensitivity, and AUC value of each detection, and the results are shown in table 5.
TABLE 5
Figure BDA0002800945270000081
Figure BDA0002800945270000091
As is clear from Table 5, the detection accuracy of each of the molecular markers mentioned in the present comparative examples against Mycobacterium avium is inferior to that of each of the molecular markers mentioned in the examples disclosed.
Comparative example 2
The Hsp65 gene sequences were determined by using base mutations at positions 184 (SNP1), 241 (SNP2), 299 (SNP3), and 346 (SNP4) from the 5' end as the detection sites in common, and the Hsp65 gene sequences in the total nucleic acid sequences of the respective mycobacteria obtained in example 2 were determined, and when the SNP1 was C, SNP2, G, SNP3, and T, SNP4 was C, the corresponding mycobacteria were determined to be mycobacterium avium, and the detection results were obtained.
ROC analysis was performed on the detection results to determine the specificity, sensitivity, and AUC values of the detection, and the results are shown in table 6.
TABLE 6
Detection of Sensitivity of the probe Specificity of AUC
Detection 20 0.503 0.995 0.749
As can be seen from Table 6, the detection sites referred to in the present comparative examples were less accurate in detection of M.avium than the respective molecular markers referred to in the disclosed examples.
The preferred embodiments of the present disclosure have been described in detail above, however, the present disclosure is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present disclosure within the technical idea of the present disclosure, and these simple modifications all fall within the protection scope of the present disclosure.
It should be noted that, in the foregoing embodiments, various features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various combinations that are possible in the present disclosure are not described again.
In addition, any combination of various embodiments of the present disclosure may be made, and the same should be considered as the disclosure of the present disclosure, as long as it does not depart from the spirit of the present disclosure.
Sequence listing
<110> Beijing coordination hospital of Chinese academy of medical sciences
<120> kit and system for detecting mycobacterium avium
<130> 17947PUMC
<160> 12
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
aactacagcg ccaacaacct 20
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
ttgacgattg actgctggag 20
<210> 3
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
gatcgaaacc cgttgaagg 19
<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
aggatcaccg acaggacgac 20
<210> 5
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
gttcgggcaa aacgacttt 19
<210> 6
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
gcgagacgaa cagataggtc a 21
<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
cgaagtcgca agacgatgta 20
<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
agtcaagctc ccttgtgcat 20
<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
gtcaagcagg gacgaaagtc 20
<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
cggttagcac cagttcccta 20
<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
tgcctgtcac tcaggaagaa 20
<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
ggggttctcc gactcaatct 20

Claims (10)

1. A kit for detecting Mycobacterium avium, comprising reagents for detecting molecular markers, wherein the molecular markers include at least one of nikA gene, ddpC gene, yejF gene, rrl G2368T site, rrl T3066A site, and acpM C177T site.
2. The kit according to claim 1, wherein the reagent for detecting a molecular marker comprises a primer pair capable of specifically amplifying the molecular marker, and/or a probe capable of specifically hybridizing to the molecular marker.
3. The kit according to claim 2, wherein the primer pair comprises at least one pair of primers shown in SEQ ID NO 1-2, SEQ ID NO 3-4, SEQ ID NO 5-6, SEQ ID NO 7-8, SEQ ID NO 9-10, and SEQ ID NO 11-12.
4. Use of a reagent for detecting a molecular marker in the preparation of a kit for detection of mycobacterium avium, wherein the molecular marker comprises at least one of nikA gene, ddpC gene, yejF gene, rrl G2368T site, rrl T3066A site, and acpM C177T site.
5. The use according to claim 4, wherein the reagent for detecting a molecular marker comprises a primer pair capable of specifically amplifying the molecular marker and/or a probe capable of specifically hybridizing to the molecular marker.
6. The use of claim 5, wherein the primer pair comprises at least one pair of primers shown in SEQ ID NO 1-2, SEQ ID NO 3-4, SEQ ID NO 5-6, SEQ ID NO 7-8, SEQ ID NO 9-10, and SEQ ID NO 11-12.
7. A system for detection of mycobacterium avium, the system comprising sequencing means, computing means and output means;
the sequencing device is used for carrying out nucleic acid sequence sequencing on the total nucleic acid of the sample to be tested to obtain a total nucleic acid sequence;
the computing device includes a memory having a computer program stored therein and a processor configured to execute the computer program stored in the memory to effect the determination of:
if the total nucleic acid sequence contains at least one of nikA gene sequence, ddpC gene sequence, yejF gene sequence, rrl G2368T site sequence, rrl T3066A site sequence and acpM C177T site sequence, judging that the mycobacterium avium exists in the sample to be detected;
the output device is used for outputting the judgment result of the computing device.
8. The system of claim 7, further comprising a nucleic acid extraction device for performing nucleic acid extraction on the sample to be tested to obtain total nucleic acids of the sample to be tested.
9. The system of claim 8, wherein the nucleic acid extraction device comprises a nucleic acid extractor and/or a nucleic acid extraction kit.
10. The system of any one of claims 7 to 9, wherein the sequencing device comprises at least one of a Sanger sequencing platform, Illumina Novaseq, HiSeq Xten, HiSeq2500/2000/4000 sequencing platform.
CN202011349925.9A 2020-11-26 2020-11-26 Kit and system for detecting mycobacterium avium Active CN112538539B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011349925.9A CN112538539B (en) 2020-11-26 2020-11-26 Kit and system for detecting mycobacterium avium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011349925.9A CN112538539B (en) 2020-11-26 2020-11-26 Kit and system for detecting mycobacterium avium

Publications (2)

Publication Number Publication Date
CN112538539A true CN112538539A (en) 2021-03-23
CN112538539B CN112538539B (en) 2022-09-23

Family

ID=75016818

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011349925.9A Active CN112538539B (en) 2020-11-26 2020-11-26 Kit and system for detecting mycobacterium avium

Country Status (1)

Country Link
CN (1) CN112538539B (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10215238C1 (en) * 2002-04-06 2003-08-14 Cytonet Gmbh & Co Kg Detecting mycobacteria and differentiating between Mycobacterium tuberculosis and Mycobacterium avium, comprises amplifying the 16S rRNA gene
US20070172838A1 (en) * 2006-01-23 2007-07-26 Edgar Ong Assay for mycobacterium avium/intracellulare nucleic acid
CN105219882A (en) * 2015-11-19 2016-01-06 北京利德曼生化股份有限公司 Mycobacterium avium-intracellulare compound group detects by primer and probe and its detection method
CN107190087A (en) * 2017-07-18 2017-09-22 武汉大学 Kit and method based on the TaqMan non-binding mycobacterias of MGB probe in detecting people and combination mycobacteria

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10215238C1 (en) * 2002-04-06 2003-08-14 Cytonet Gmbh & Co Kg Detecting mycobacteria and differentiating between Mycobacterium tuberculosis and Mycobacterium avium, comprises amplifying the 16S rRNA gene
US20070172838A1 (en) * 2006-01-23 2007-07-26 Edgar Ong Assay for mycobacterium avium/intracellulare nucleic acid
CN105219882A (en) * 2015-11-19 2016-01-06 北京利德曼生化股份有限公司 Mycobacterium avium-intracellulare compound group detects by primer and probe and its detection method
CN107190087A (en) * 2017-07-18 2017-09-22 武汉大学 Kit and method based on the TaqMan non-binding mycobacterias of MGB probe in detecting people and combination mycobacteria

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GENBANK: "Genbank Accession:CP046507", 《GENBANK》, 11 December 2019 (2019-12-11) *
JIA ET AL.: "Combining comparative genomic analysis with machine learning reveals some promising diagnostic markers to identify five common pathogenic non-tuberculous mycobacteria", 《MICROBIAL BIOTECHNOLOGY》, 21 May 2021 (2021-05-21) *

Also Published As

Publication number Publication date
CN112538539B (en) 2022-09-23

Similar Documents

Publication Publication Date Title
Vasar et al. Increased sequencing depth does not increase captured diversity of arbuscular mycorrhizal fungi
Platonov et al. Molecular typing of Yersinia pestis
JP2005504508A5 (en)
JP2009502137A (en) Method for rapid identification and quantification of nucleic acid variants
Kong et al. secA1 gene sequence polymorphisms for species identification of Nocardia species and recognition of intraspecies genetic diversity
Carrasco et al. Identification, typing, and phylogenetic relationships of the main clinical Nocardia species in Spain according to their gyrB and rpoB genes
CN111500771A (en) Primer group and kit for detecting novel coronavirus SARS-CoV-2
Chiu et al. Next‐generation sequencing
CN104995314A (en) Primers, snp markers and method for genotyping mycobacterium tuberculosis
CN108138244A (en) Virus group capture microarray dataset, design and construction method and application method
WO2017139715A1 (en) Systems and methods for the detection of infectious diseases
Abdel-Glil et al. Phylogenomic analysis of Campylobacter fetus reveals a clonal structure of insertion element ISCfe1 positive genomes
Gallardo et al. A multi gene-approach genotyping method identifies 24 genetic clusters within the genotype II-European African swine fever viruses circulating from 2007 to 2022
CN112538539B (en) Kit and system for detecting mycobacterium avium
CN115786541B (en) SNP molecular marker, primer probe, kit, method and application for identifying Brucella vaccine strain A19
CN112538538B (en) Kit and system for detecting mycobacterium abscessus
CN112538542B (en) Kit and system for detecting mycobacterium cheloni
CN112538541B (en) Kit and system for detecting M.intracellulare
CN112538540B (en) Kit and system for detecting mycobacterium kansasii
Read et al. PCR bias associated with conserved primer binding sites, used to determine genotype diversity within Citrus tristeza virus populations
Gorden et al. Next generation sequencing of STR artifacts produced from historical bone samples
US11359251B2 (en) Methods for the detection of enterovirus D68 in complex samples
CN106498069A (en) For detecting the specific primer of Drug-Resistant Mycobacterium tuberculosis KatG gene Cs 906A mutation
CN112553350A (en) Method for rapidly detecting multiple mycobacteria
CN105886622A (en) Primer and method for fast typing campylobacter jejuni

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant